Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884
Debt
Debt-to-Equity RatioN/A
Current Ratio7.82
Quick Ratio7.82
Price-To-Earnings
Trailing P/E Ratio-10.93
Forward P/E Ratio-11.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales970.21
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book5.16
Profitability
EPS (Most Recent Fiscal Year)($1.78)
Net Income$-25,490,000.00
Net Margins-10,133.88%
Return on Equity-47.52%
Return on Assets-44.44%
Miscellaneous
Employees125
Outstanding Shares16,960,000
Market Cap$324.82 million
Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions
What is Cellular Biomedicine Group's stock symbol?
Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."
How will Cellular Biomedicine Group's stock buyback program work?
Cellular Biomedicine Group announced that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $10,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.
How were Cellular Biomedicine Group's earnings last quarter?
Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.52) by $0.01. The biotechnology company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. Cellular Biomedicine Group had a negative net margin of 10,133.88% and a negative return on equity of 47.52%. View Cellular Biomedicine Group's Earnings History.
When is Cellular Biomedicine Group's next earnings date?
What price target have analysts set for CBMG?
2 brokers have issued 12-month price objectives for Cellular Biomedicine Group's stock. Their forecasts range from $18.00 to $32.00. On average, they expect Cellular Biomedicine Group's share price to reach $25.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.
What is the consensus analysts' recommendation for Cellular Biomedicine Group?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.
What are Wall Street analysts saying about Cellular Biomedicine Group stock?
Here are some recent quotes from research analysts about Cellular Biomedicine Group stock:
- 1. According to Zacks Investment Research, "Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California. " (7/23/2018)
- 2. Maxim Group analysts commented, "As Gilead pays $12 Billion for the planned acquisiton of Kite (KITE – $178.28 – Hold) and the market shifts focus to the remaining stand-alone CAR-T players such as JUNO (JUNO – $43.67 – Buy) and bluebird (BLUE – $103.88 – Buy) we see an opportunity with CBMG in China." (8/29/2017)
Who are some of Cellular Biomedicine Group's key competitors?
Some companies that are related to Cellular Biomedicine Group include Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Autolus Therapeutics (AUTL), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Adaptimmune Therapeutics (ADAP), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), CASI Pharmaceuticals (CASI), Voyager Therapeutics (VYGR), La Jolla Pharmaceutical (LJPC), Fate Therapeutics (FATE) and Mesoblast (MESO).
Who are Cellular Biomedicine Group's key executives?
Cellular Biomedicine Group's management team includes the folowing people:
- Mr. Bizuo Liu, CEO, CFO & Director (Age 53)
- Dr. Yihong Yao, Chief Scientific Officer (Age 50)
- Mr. Andrew K. Chan, Sr. VP of Corp. Bus. Devel., Sec. & Chief Legal Officer (Age 60)
- Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
- Ms. Sarah Kelly, Director of Corp. Communications
Has Cellular Biomedicine Group been receiving favorable news coverage?
News headlines about CBMG stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellular Biomedicine Group earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Cellular Biomedicine Group.
Who are Cellular Biomedicine Group's major shareholders?
Cellular Biomedicine Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.37%), Bank of New York Mellon Corp (0.20%), Schwab Charles Investment Management Inc. (0.12%) and Rhumbline Advisers (0.06%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.
Which major investors are buying Cellular Biomedicine Group stock?
CBMG stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Rhumbline Advisers. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.
How do I buy shares of Cellular Biomedicine Group?
Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Biomedicine Group's stock price today?
One share of CBMG stock can currently be purchased for approximately $19.45.
How big of a company is Cellular Biomedicine Group?
Cellular Biomedicine Group has a market capitalization of $324.82 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.
How can I contact Cellular Biomedicine Group?
Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]
MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
